🧠 Watchlist Winners: Copy Legendary Investors' Portfolios in One ClickCOPY FOR FREE

Equillium Inc (EQ)

NASDAQ
Currency in USD
Disclaimer
0.890
+0.011(+1.30%)
Real-time Data
EQ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.8520.938
52 wk Range
0.4503.250
Prev. Close
0.87
Open
0.904
Day's Range
0.852-0.938
52 wk Range
0.45-3.25
Volume
65,740
Average Vol. (3m)
148,631
1-Year Change
11.51%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
EQ Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.750
Upside
+658.427%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Equillium Inc Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Employees
44

Compare EQ to Peers and Sector

Metrics to compare
EQ
Peers
Sector
Relationship
P/E Ratio
−3.9x−0.5x−0.6x
PEG Ratio
−0.070.020.00
Price / Book
1.4x0.4x2.6x
Price / LTM Sales
0.8x1.9x3.1x
Upside (Analyst Target)
704.6%187.6%57.6%
Fair Value Upside
Unlock23.9%7.3%Unlock

People Also Watch

13.6100
GYRE
-0.87%
0.698
DXYN
+2.77%
2.805
VNET
-2.94%
2.830
GALT
+4.43%
1.180
OVID
+6.31%

FAQ

What Is the Equillium (EQ) Stock Price Today?

The Equillium stock price today is 0.89

What Stock Exchange Does Equillium Trade On?

Equillium is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Equillium?

The stock symbol for Equillium is "EQ."

What Is the Equillium Market Cap?

As of today, Equillium market cap is 30.18M.

What is Equillium Earnings Per Share?

The Equillium EPS is -0.237.

What Is the Next Equillium Earnings Date?

Equillium will release its next earnings report on Nov 12, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.